Bridging, switching or drug holidays - How to treat a patient who stops natalizumab?

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 361-369

  Havla, Joachim ^a   Kleiter, Ingo ^b   Kümpfel, Tania ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Bridging; Drug holidays; Multiple sclerosis; Natalizumab discontinuation; Switching

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RALENOVA; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

AUTOIMMUNE THROMBOCYTOPENIA; BRADYCARDIA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMOLYTIC ANEMIA; HERPES VIRUS INFECTION; HUMAN; HYPEREOSINOPHILIA; LYMPHOCYTOSIS; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RETINA MACULA EDEMA; REVIEW; SKIN CANCER; TREATMENT OUTCOME;

EID: 84889806212     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S41552     Document Type: Review

References (70)

1. Polman CH, O'Connor PW, Havrdova E, etal. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Rudick RA, Stuart WH, Calabresi PA, etal. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9): 911-923.
3. Bloomgren G, Richman S, Hotermans C, etal. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
4. Gorelik L, Lerner M, Bixler S, etal. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
5. Bozic C, Richman S, Plavina T, etal. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70(5):742-750.
6. Trampe AK, Hemmelmann C, Stroet A, etal. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78(22):1736-1742.
7. Plavina T, Lee S, Berman M, etal. Longitudinal stability of anti-JC virus antibody status in multiple sclerosis patients: results of STRATIFY-1 (S30.001). Neurology. 2013;80 (Meeting Abstracts 1):S30.001.
8. Derfuss T, Kuhle J, Lindberg R, Kappos L. Natalizumab therapy for multiple sclerosis. Semin Neurol. 2013;33(1):26-36.
9. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology. 2012;78(7):507-508.
10. Yousry TA, Pelletier D, Cadavid D, etal. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779-787.
11. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kumpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64(9):1331-1333.
12. Sorensen PS, Jensen PE, Haghikia A, etal. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011;17(9):1074-1078.
13. Oliver B, Fernandez O, Orpez T, etal. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler. 2011;17(3):368-371.
14. Oliver-Martos B, Orpez-Zafra T, Urbaneja P, Maldonado-Sanchez R, Leyva L, Fernandez O. Early development of anti-natalizumab antibodies in MS patients. J Neurol. 2013 Jun 14. [Epub ahead of print.]
15. Abbas M, Lalive PH, Chofflon M, Simon HU, Chizzolini C, Ribi C. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. Neurology. 2011;77(16):1561-1564.
16. Schweikert A, Kremer M, Ringel F, etal. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66(3):403-406.
17. Ransohoff RM. Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum. Ann Neurol. 2009;66(3):259-261.
18. Schowinsky J, Corboy J, Vollmer T, Kleinschmidt-DeMasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropath. 2012;123(5):751-752.
19. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med. 2008;358(6):647-648.
20. Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359(1):99; author reply 99-100.
21. Castela E, Lebrun-Frenay C, Laffon M, etal. Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol. 2011;147(1): 72-76.
22. Leussink VI, Lehmann HC, Meyerzu Horste G, Hartung HP, Stuve O, Kieseier BC. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol. 2008;255(9):1436-1438.
23. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958-963.
24. Stuve O, Marra CM, Jerome KR, etal. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5): 743-747.
25. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13 Pt 2):1150-1151.
26. Stuve O, Cravens PD, Frohman EM, etal. Immunologic, clinical, and radiologic status 14months after cessation of natalizumab therapy. Neurology. 2009;72(5):396-401.
27. Cree B, De Seze J, Fox R, etal. Natalizumab effects during a 6-month dose Interruption: relationship of pharmacokinetic (PK), pharmacodynamic (PD), and MRI measurements (S41.003). Neurology. 2013;80(Meeting Abstracts 1):S41.003.
28. Havla J, Gerdes LA, Meinl I, etal. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258(9):1665-1669.
29. O'Connor PW, Goodman A, Kappos L, etal. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858-1865.
30. Kappos L, Bates D, Edan G, etal. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745-758.
31. Killestein J, Vennegoor A, Strijbis EM, etal. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392-395.
32. Rigau V, Mania A, Befort P, etal. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214-2216.
33. Fox R, Kappos L, Cree B, etal, editors. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. 5th Joint Triennial Congress of the European and Americas Committees for Treatment an d Research in Multiple Sclerosis, October 19-22;2011; Amsterdam, The Netherlands.
34. Clerico M, De Mercanti S, Piazza F, etal. Natalizumab discontinuation after the 24th course: which is way? The TY-STOP Study (P01.197). Neurology. 2013;80(Meeting Abstracts 1):P01.197.
35. Lenhard T, Biller A, Mueller W, Metz I, Schonberger J, Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology. 2010;75(9):831-833.
36. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2):186-191.
37. Papeix C, Depaz R, Tourbah A, Stankoff B, Lubetzki C. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult Scler. 2011;17(12): 1520-1522.
38. Borriello G, Prosperini L, Mancinelli C, Gianni C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol. 2012;19(5):783-787.
39. Magraner MJ, Coret F, Navarre A, etal. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol. 2011;258(10):1805-1811.
40. Gobbi C, Meier DS, Cotton F, etal. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013;13:101.
41. Rossi S, Motta C, Studer V, etal. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87-94.
42. Kappos L, Radue EW, O'Connor P, etal. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
43. Cohen JA, Barkhof F, Comi G, etal. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Mws. 2010;362(5): 402-415.
44. Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kumpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69(2):262-264.
45. Lysandropoulos AP, Benghiat F. Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Mult Scler. 2013 Jul1. [Epub ahead of print.]
46. Gross CM, Baumgartner A, Rauer S, Stich O. Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Neurology. 2012;79(19):2006-2007.
47. Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology. 2012;79(19):2002-2004.
48. Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012;79(19):2000-2003.
49. Havla J, Tackenberg B, Hellwig K, etal. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol. 2013;260(5):1382-1387.
50. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler. 2012;18(11):1640-1643.
51. Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Mult Scler. 2013;19(9):1236-1237.
52. Centonze D, Rossi S, Rinaldi F, Gallo P. Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology. 2012;79(19): 2004-2005.
53. Castrop F, Kowarik MC, Albrecht H, etal. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? Neurology. 2012;78(12):928-930.
54. Daelman L, Maitrot A, Maarouf A, Chaunu M, Papeix C, Tourbah A. Severe multiple sclerosis reactivation under fingolimod 3months after natalizumab withdrawal. Mult Scler. 2012;18(11):1647-1649.
55. Jander S, Turowski B, Kieseier BC, Hartung HP. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012;18(11):1650-1652.
56. Comi G, Gold R, Dahlke F, etal. Relapse outcomes in fingolimod-treated patients previously exposed to natalizumab: post-hoc analysis from the 4-month, open-label FIRST study (P07.103). Neurology. 2013;80(Meeting Abstracts 1):P07.103.
57. Cohen M, Maillart E, Papeix C, etal. ENIGM: A French observational study about switching from natalizumab to fingolimod in multiple sclerosis (S41.002). Neurology. 2013;80(Meeting Abstracts 1):S41.002.
58. O'Connor P, Wolinsky JS, Confavreux C, etal. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
59. Phillips JT, Fox RJ. BG-12in multiple sclerosis. Sem Neurol. 2013;33(1):56-65.
60. Fox RJ, Miller DH, Phillips JT, etal. Placebo-controlled phase 3study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
61. Gold R, Kappos L, Arnold DL, etal. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
62. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658-1659.
63. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368(17):1659-1661.
64. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657-1658.
65. Cohen JA, Coles AJ, Arnold DL, etal. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
66. Coles AJ, Twyman CL, Arnold DL, etal. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856): 1829-1839.
67. Coles AJ. Alemtuzumab treatment of multiple sclerosis. Sem Neurol. 2013;33(1):66-73.
68. Kaufman MD, Lee R, Norton H. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler. 2011;17(4):490-494.
69. Hauser SL, Waubant E, Arnold DL, etal. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7): 676-688.
70. Stuve O, Leussink VI, Frohlich R, etal. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66(2):259-261.